TRxA recently hosted a webinar detailing the funding opportunities afforded by TRxA’s BRIDGe Awards.
TRxA’s focus is translating early-stage novel therapeutics into Investigational New Drug (IND) supporting data packages that garner interest for licensing opportunities; we are helping “BRIDGe” (Breakthrough Research and Innovation in Drug Development Grants) the drug development valley of death. Projects eligible for TRxA BRIDGe funding and support include early lead optimization through IND-enabling studies of small molecule therapeutics. Biologics, including natural peptides or antibodies, cell and gene therapy applications, and diagnostic and medical devices are not eligible at this time; nor are drug repurposing initiatives.
View the recording here.
